15 Bordetella bronchiseptica (B. bronchiseptica) is an etiologic agent of respiratory 16 diseases in animals and humans. Despite widespread use of veterinary B. 17 bronchiseptica vaccines, there is limited information on their composition, relative 18 efficacy, and the immune responses they elicit. Furthermore, human B. bronchiseptica 19 vaccines are not available. We leveraged the dual antigenic and adjuvant functions of 20 BcfA to develop acellular B. bronchiseptica vaccines in the absence of an additional 21 adjuvant. Balb/c mice immunized with BcfA alone or a trivalent vaccine containing BcfA 22 and the Bordetella antigens FHA and Prn were equally protected against challenge with 23 a prototype B. bronchiseptica strain. The trivalent vaccine protected mice significantly 24 better than the canine vaccine Bronchicine ® and provided protection against a B. 25 bronchiseptica strain isolated from a dog with kennel cough. Th1/17-polarized immune 26 responses correlate with long-lasting protection against Bordetellae and other 27 respiratory pathogens. Notably, BcfA strongly attenuated the Th2 responses elicited by 28 FHA/Prn, resulting in Th1/17-skewed responses in inherently Th2-skewed Balb/c mice. 29 Thus, BcfA functions as both an antigen and an adjuvant, providing protection as a 30 single component vaccine. BcfA-adjuvanted vaccines may improve the efficacy and 31 durability of vaccines against Bordetellae and other pathogens.
INTRODUCTION
FHA and Prn alone or adjuvanted to alum elicit Th2-skewed antibody 141 responses(25). To determine whether BcfA remodeled these responses towards Th1 142 we evaluated the systemic and mucosal IgG levels and calculated the ratio of FHA-and 143 Prn-specific IgG2/IgG1 antibodies elicited by BcfA/FHA/Prn. FHA-specific IgG was 144 higher in the serum ( Fig 4A) and lungs ( Fig 4C) of FHA/Prn-and BcfA/FHA/Prn- 145 immunized mice compared to naïve mice, while Prn-specific antibody levels were 146 8 increased in the serum ( Fig 4B) , but not the lungs ( Fig 4D) . We observed a higher ratio 147 of FHA-specific IgG2b/IgG1 in the serum ( Fig 4E) and lungs ( Fig 4G) of mice 148 immunized with BcfA/FHA/Prn compared to FHA/Prn alone. These data suggest that 149 the adjuvant function of BcfA shifts the antibody response to FHA toward Th1 by 150 reducing the Th2-type antibodies. In contrast, the Prn-specific antibody ratios were not 151 altered (FIG 4F) .
152
Immunization with BcfA/FHA/Prn elicits Th1/17 cytokine production and 153 attenuates Th2 cytokine production. 154 We showed that murine bone marrow dendritic cells stimulated with BcfA immunized mice. Together, these results show that, by inhibiting the production of Th2 170 cytokines, BcfA skews responses away from Th2 and toward Th1/Th17 in a Th2-prone 171 mouse strain.
172
BcfA/FHA/Prn provides better protection against a laboratory and a clinical strain 173 of B. bronchiseptica than a commercial cellular antigen extract vaccine. 174 We compared protection provided by BcfA or BcfA/FHA/Prn to that provided by 175 Bronchicine ® , a widely used but insufficiently characterized veterinary vaccine. Mice 176 were immunized with BcfA/FHA/Prn or BcfA as above or with 1/10 th or 1/5 th canine dose 177 of Bronchicine ® , doses similar to those of human aPV commonly tested in mice (25, 38) .
178
Immunized and naïve mice were subsequently challenged with RB50 or with MBORD 179 685, a canine B. bronchiseptica strain isolated from a dog with kennel cough(3). Overall, 180 colonization of the respiratory tract of naïve and immunized mice by MBORD 685 was 181 equivalent to colonization by the rabbit isolate RB50 (Fig 6A,B) . While all four 182 immunizations reduced bacterial burden compared to naïve mice, BcfA/FHA/Prn 183 immunization most efficiently reduced bacterial burden in the lungs ( Fig 6A) and trachea 184 ( Fig 6B) . Immunization with BcfA alone was significantly more protective than 1/10 th but 185 not 1/5 th dose Bronchicine ® in both the lungs ( Fig 6A) and trachea ( Fig 6B) . Importantly, 186 both doses of Bronchicine ® were significantly less protective in the lungs of immunized 187 mice than BcfA/FHA/Prn ( Fig 6A) . The lungs of 83% of mice immunized with 188 BcfA/FHA/Prn were cleared of B. bronchiseptica below the limit of detection while only -189 23% and 50% were cleared by 1/10 and 1/5 dose Bronchicine ® , respectively ( Fig 6A) .
190
Together, these results support the clinical applicability of either monovalent BcfA or 191 10 trivalent BcfA/FHA/Prn as veterinary vaccines and provide a new avenue for more 192 effective and, potentially, durable protection against this pathogen.
193
BcfA/FHA/Prn elicits more robust antigen-specific antibody responses than a 194 commercial veterinary vaccine. 195 We observed similar FHA-and Prn-specific antibody levels between 1/10 196 Bronchicine ® -immunized mice and naïve mice (see Fig 4) . In contrast, immunization Table 1 ). As 207 expected, total pathology score for naïve challenged mice ( Fig 7A) was highest, There is an urgent need for improved vaccines against B. bronchiseptica since 221 respiratory diseases caused by this pathogen are a significant health concern for 222 animals and humans. Although vaccines are widely used in veterinary medicine to Though alum has been used successfully as a vaccine adjuvant since the early 231 1900s to prevent disease, it elicits Th2-skewed responses and thus weaker and shorter-232 lived immunity(40). Thus, substituting alum with Th1/17 polarizing adjuvants is likely to 233 improve vaccine-induced immunity. We previously showed that BcfA elicits Th1/17 234 responses in C57BL/6 mice(25). To determine the full potential of BcfA in the absence 235 of alum to mediate protective shifts in immune responses, we administered BcfA-236 containing vaccines to the Th2-prone mouse strain, Balb/c(37). Cellular and humoral 237 responses to BcfA, FHA, and Prn were remodeled to Th1/17, primarily by attenuating 238 Th2 cytokine production. This also resulted in a higher ratio of IgG2/IgG1 antibodies. Thus, it is notable that the BcfA-containing vaccine characterized in this study 248 attenuates the Th2 responses elicited by FHA. 249 We hypothesized that the trivalent BcfA/FHA/Prn vaccine would be more 250 effective than BcfA alone due to the presence of two additional antigens. Surprisingly, 251 the protection provided by this combination was not significantly better than BcfA alone, 252 although cytokine and antibody responses to FHA were detected. We did not detect 253 strong responses to Prn, suggesting that this antigen may be dispensable. that Prn-specific responses may not be protective due to antigenic drift among 256 circulating strains. We showed previously that B. bronchiseptica isolates from dogs 257 (including MBORD 685 used in this study), cats, horses, pigs, and humans highly 
